EMIL D KAKKIS Insider Trading $RARE Ultragenyx Pharmaceutical Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for EMIL D KAKKIS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of EMIL D KAKKIS. EMIL D KAKKIS is SVP, Business Operations in BIOMARIN PHARMACEUTICAL INC ($BMRN) and President & CEO in Ultragenyx Pharmaceutical Inc. ($RARE).
EMIL D KAKKIS in Ultragenyx Pharmaceutical Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of EMIL D KAKKIS: President & CEO
Holdings: 595,200 shares
Current Value: $43,396,032
Latest Transaction: May 10 2021
$RARE Market Capitalization: $2.92B
$RARE Previous Close: $72.91
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of EMIL D KAKKIS in Ultragenyx Pharmaceutical Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 10 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 115.71 | 852 | 98,585 | 595,200 | 596.1 K to 595.2 K (-0.14 %) |
| May 05 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 107.80 | 30,000 | 3,234,000 | 2,259,741 | 2.3 M to 2.3 M (-1.31 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | A | 142.47 | 36,000 | 5,128,920 | 36,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 141.80 | 30,000 | 4,254,000 | 2,289,741 | 2.3 M to 2.3 M (-1.29 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 142.47 | 16,342 | 2,328,245 | 596,052 | 612.4 K to 596.1 K (-2.67 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 15,453 | 0 | 612,394 | 596.9 K to 612.4 K (+2.59 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 18,000 | 0 | 596,941 | 578.9 K to 596.9 K (+3.11 %) |
| Nov 04 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 96.82 | 30,000 | 2,904,600 | 2,359,741 | 2.4 M to 2.4 M (-1.26 %) |
| Oct 16 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 92.69 | 852 | 78,972 | 610,189 | 611 K to 610.2 K (-0.14 %) |
| Sep 02 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 82.63 | 30,000 | 2,478,900 | 2,389,741 | 2.4 M to 2.4 M (-1.24 %) |
| Jul 15 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 85.35 | 40,000 | 3,414,000 | 2,419,741 | 2.5 M to 2.4 M (-1.63 %) |
| Jun 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 69.38 | 1,334 | 92,553 | 611,041 | 612.4 K to 611 K (-0.22 %) |
| May 08 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 66.26 | 852 | 56,454 | 652,797 | 653.6 K to 652.8 K (-0.13 %) |
| Apr 21 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 58.57 | 851 | 49,843 | 653,649 | 654.5 K to 653.6 K (-0.13 %) |
| Mar 13 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | X | 3.01 | 66,533 | 199,998 | 0 | |
| Mar 13 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | X | 3.01 | 83,167 | 250,000 | 0 | |
| Mar 13 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Buy | X | 3.01 | 66,533 | 199,998 | 654,500 | 588 K to 654.5 K (+11.32 %) |
| Mar 13 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Buy | X | 3.01 | 83,167 | 250,000 | 587,967 | 504.8 K to 588 K (+16.48 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | A | 56.08 | 56,100 | 3,146,088 | 56,100 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 56.08 | 6,896 | 386,728 | 504,800 | 511.7 K to 504.8 K (-1.35 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 18,782 | 0 | 511,696 | 492.9 K to 511.7 K (+3.81 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 17,000 | 0 | 492,914 | 475.9 K to 492.9 K (+3.57 %) |
| Oct 16 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 3,435 | 0 | 475,914 | 472.5 K to 475.9 K (+0.73 %) |
| Sep 11 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Buy | P | 43.63 | 5,000 | 218,150 | 472,479 | 467.5 K to 472.5 K (+1.07 %) |
| Sep 11 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Buy | P | 43.63 | 5,000 | 218,150 | 472,479 | 467.5 K to 472.5 K (+1.07 %) |
| Jun 04 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 54.93 | 1,327 | 72,892 | 467,479 | 468.8 K to 467.5 K (-0.28 %) |
| May 22 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 59.50 | 1,414 | 84,133 | 468,806 | 470.2 K to 468.8 K (-0.30 %) |
| May 07 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 3,435 | 0 | 470,220 | 466.8 K to 470.2 K (+0.74 %) |
| Apr 23 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 64.43 | 798 | 51,415 | 466,785 | 467.6 K to 466.8 K (-0.17 %) |
| Mar 04 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | A | 67.55 | 66,000 | 4,458,300 | 66,000 | |
| Mar 04 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 67.55 | 2,802 | 189,275 | 467,670 | 470.5 K to 467.7 K (-0.60 %) |
| Mar 04 2019 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 20,000 | 0 | 470,472 | 450.5 K to 470.5 K (+4.44 %) |
| Jun 04 2018 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 73.73 | 926 | 68,274 | 450,472 | 451.4 K to 450.5 K (-0.21 %) |
| May 22 2018 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 64.79 | 986 | 63,883 | 451,398 | 452.4 K to 451.4 K (-0.22 %) |
| Apr 19 2018 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 3,429 | 0 | 452,384 | 449 K to 452.4 K (+0.76 %) |
| Aug 29 2017 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Buy | P | 52.96 | 1,647 | 87,225 | 2,559,741 | 2.6 M to 2.6 M (+0.06 %) |
| Aug 29 2017 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Buy | P | 52.40 | 5,853 | 306,697 | 2,558,094 | 2.6 M to 2.6 M (+0.23 %) |
| Jun 01 2017 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 56.61 | 1,006 | 56,950 | 430,569 | 431.6 K to 430.6 K (-0.23 %) |
| May 22 2017 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 57.47 | 1,072 | 61,608 | 431,575 | 432.6 K to 431.6 K (-0.25 %) |
| Mar 01 2017 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | A | 88.80 | 78,000 | 6,926,400 | 78,000 | |
| Mar 01 2017 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 13,000 | 0 | 432,647 | 419.6 K to 432.6 K (+3.10 %) |
| Nov 17 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 83.01 | 200 | 16,602 | 447,147 | 447.3 K to 447.1 K (-0.04 %) |
| Nov 17 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 82.36 | 4,180 | 344,265 | 447,347 | 451.5 K to 447.3 K (-0.93 %) |
| Nov 17 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 81.55 | 7,755 | 632,420 | 451,527 | 459.3 K to 451.5 K (-1.69 %) |
| Nov 17 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 80.64 | 6,451 | 520,209 | 459,282 | 465.7 K to 459.3 K (-1.39 %) |
| Nov 17 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 79.39 | 1,414 | 112,257 | 465,733 | 467.1 K to 465.7 K (-0.30 %) |
| Oct 18 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 64.78 | 1,800 | 116,604 | 467,147 | 468.9 K to 467.1 K (-0.38 %) |
| Oct 18 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 64.41 | 2,345 | 151,041 | 468,947 | 471.3 K to 468.9 K (-0.50 %) |
| Oct 18 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 63.06 | 9,340 | 588,980 | 471,292 | 480.6 K to 471.3 K (-1.94 %) |
| Oct 18 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 61.97 | 6,515 | 403,735 | 480,632 | 487.1 K to 480.6 K (-1.34 %) |
| Aug 17 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 68.12 | 6,097 | 415,328 | 487,147 | 493.2 K to 487.1 K (-1.24 %) |
| Aug 17 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 67.39 | 13,903 | 936,923 | 493,244 | 507.1 K to 493.2 K (-2.74 %) |
| Jul 19 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 51.34 | 6,450 | 331,143 | 507,147 | 513.6 K to 507.1 K (-1.26 %) |
| Jul 19 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 50.61 | 13,550 | 685,766 | 513,597 | 527.1 K to 513.6 K (-2.57 %) |
| Jun 03 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | A | 70.57 | 63,700 | 4,495,309 | 63,700 | |
| Jun 03 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 10,700 | 0 | 527,147 | 516.4 K to 527.1 K (+2.07 %) |
| May 24 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 64.01 | 1,072 | 68,619 | 516,447 | 517.5 K to 516.4 K (-0.21 %) |
| May 18 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 61.93 | 200 | 12,386 | 517,519 | 517.7 K to 517.5 K (-0.04 %) |
| May 18 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 61.34 | 2,595 | 159,177 | 517,719 | 520.3 K to 517.7 K (-0.50 %) |
| May 18 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 60.32 | 6,390 | 385,445 | 520,314 | 526.7 K to 520.3 K (-1.21 %) |
| May 18 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 59.37 | 10,815 | 642,087 | 526,704 | 537.5 K to 526.7 K (-2.01 %) |
| Apr 19 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 71.06 | 5,376 | 382,019 | 537,519 | 542.9 K to 537.5 K (-0.99 %) |
| Apr 19 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 70.35 | 9,834 | 691,822 | 542,895 | 552.7 K to 542.9 K (-1.78 %) |
| Apr 19 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 69.46 | 4,790 | 332,713 | 552,729 | 557.5 K to 552.7 K (-0.86 %) |
| Jan 04 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 114.61 | 605 | 69,339 | 575,640 | 576.2 K to 575.6 K (-0.10 %) |
| Jan 04 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 113.83 | 2,702 | 307,569 | 576,245 | 578.9 K to 576.2 K (-0.47 %) |
| Jan 04 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 112.91 | 2,191 | 247,386 | 578,947 | 581.1 K to 578.9 K (-0.38 %) |
| Jan 04 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 116.31 | 2,600 | 302,406 | 581,138 | 583.7 K to 581.1 K (-0.45 %) |
| Jan 04 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 115.56 | 3,600 | 416,016 | 583,738 | 587.3 K to 583.7 K (-0.61 %) |
| Jan 04 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 114.61 | 5,465 | 626,344 | 587,338 | 592.8 K to 587.3 K (-0.92 %) |
| Jan 04 2016 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 113.30 | 2,837 | 321,432 | 592,803 | 595.6 K to 592.8 K (-0.48 %) |
| Dec 02 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 99.42 | 1,415 | 140,679 | 595,640 | 597.1 K to 595.6 K (-0.24 %) |
| Dec 02 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 98.62 | 11,374 | 1,121,704 | 597,055 | 608.4 K to 597.1 K (-1.87 %) |
| Dec 02 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 97.88 | 5,261 | 514,947 | 608,429 | 613.7 K to 608.4 K (-0.86 %) |
| Dec 02 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 96.46 | 1,950 | 188,097 | 613,690 | 615.6 K to 613.7 K (-0.32 %) |
| Nov 03 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 101.20 | 1,900 | 192,280 | 615,640 | 617.5 K to 615.6 K (-0.31 %) |
| Nov 03 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 100.43 | 4,400 | 441,892 | 617,540 | 621.9 K to 617.5 K (-0.71 %) |
| Nov 03 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 99.42 | 7,600 | 755,592 | 621,940 | 629.5 K to 621.9 K (-1.21 %) |
| Nov 03 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 98.63 | 6,100 | 601,643 | 629,540 | 635.6 K to 629.5 K (-0.96 %) |
| May 27 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | A | 84.89 | 68,300 | 5,797,987 | 68,300 | |
| May 27 2015 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 11,400 | 0 | 635,640 | 624.2 K to 635.6 K (+1.83 %) |
Page: 1